Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00161668 · ClinicalTrials.gov registry record
Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care
A clinical trial, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- 500
- Enrollment target
NCT00161668: Completed study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
NCT00161668 is a clinical trial that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 500 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00161668 has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- 500 participants
- Enrollment target
Study Summary
This study is designed to assess the safety of Mylotarg therapy in routine practice.
Interventions
- DRUG Mylotarg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2001-10 |
What the finished NCT00161668 record still lists
NCT00161668 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Mylotarg is the first listed.
NCT00161668 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00161668 about?
NCT00161668 is a clinical study titled "Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care". This study is designed to assess the safety of Mylotarg therapy in routine practice.
What is the current status of trial NCT00161668?
This trial is currently completed. The enrollment target is 500 participants. The study started on 2001-10.
What interventions are being tested in trial NCT00161668?
The interventions under investigation include: Mylotarg (DRUG).
Who is sponsoring clinical trial NCT00161668?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia